CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
STAT3d
Editas, after slow start, outlines plan to catch other CRISPR companies
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
AZoLifeSciences on MSN2d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapies
Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
foodengineeringmag2d
Understanding the Regulatory Challenges for CRISPR Gene Editing on Crops
CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...
openaccessgovernment16d
CRISPR/ Diagnostics: A portable lab for everyone
Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
Contract Pharma6d
Synthego, AstraZeneca Ink Agreement for CRISPR Gene Editing Enzyme
Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.